Ackermans & van Haaren supports MRM Health’s Series B financing round of 55 million euros

Group 1 - Ackermans & van Haaren (AvH) supports a Series B financing round of 55 million euros for MRM Health, a clinical-stage biopharmaceutical company focused on microbiome-based therapeutics for inflammatory diseases and immune-oncology [1] - AvH's additional investment in this financing round amounts to 3 million euros, increasing its total investment in MRM Health to 10.8 million euros [1] - AvH's fully diluted participation in MRM Health is now 14.1% following this investment [1]